Journal
EMERGING INFECTIOUS DISEASES
Volume 6, Issue 6, Pages 585-594Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid0606.000606
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI 33061, AI45473] Funding Source: Medline
Ask authors/readers for more resources
We examined the long-term efficacy of praziquantel against Schistosoma haematobium, the causative agent of urinary schistosomiasis, during a school-based treatment program in the Msambweni area of Coast Province, Kenya, where the disease is highly endemic. Our results, derived from treating 4,031 of 7,641 children from 1984 to 1993, indicate substantial year-to-year Variation in drug efficacy. However, the pattern of this variation was not consistent with primary or progressive emergence of praziquantel resistance. Mathematical modeling indicated that, at current treatment rates, praziquantel resistance will likely take 10 or more years to emerge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available